<DOC>
	<DOCNO>NCT02001896</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety treatment erlotinib intercalate platinum-based therapy erlotinib along , first line treatment Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor ( EGFR ) Mutation . Patients randomize receive gemcitabine ( 1000mg/m2 iv ) day 1 , cisplatin ( 75mg/m2 ) carboplatin ( 5xAUC ) day 1 , follow erlotinib 150mg/day day 15 day 28 4 week cycle total 6 cycle , follow erlotinib monotherapy , erlotinib 150mg/day .The anticipated time study treatment disease progression , target sample size 60 individual .</brief_summary>
	<brief_title>Erlotinib Intercalated With Chemotherapy Versus Erlotinib First Line Treatment Stage IIIB/IV NSCLC Patients With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; advance ( stage IIIB/IV ) nonsmall cell lung cancer ; measurable disease ; ECOG Performance Status 02. prior exposure agent direct HER axis ; prior chemotherapy systemic antitumor therapy advance disease ; unstable systemic disease ; malignancy within last 5 year , except cure basal cell cancer skin cure cancer situ cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR-TKI</keyword>
</DOC>